Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
NCT06275919Phase 2Recruiting
- Sponsor
- Istituto Oncologico Veneto
- Start
- Sep 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in meningioma, sponsored by Istituto Oncologico Veneto. Started Sep 2024; status: recruiting.
02
Drugs
regorafenib
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT06275919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275919.